Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OncoMed Pharmaceuticals Inc and Celgene Corp enter into agreement - Reuters


Tuesday, 3 Dec 2013 08:11am EST 

OncoMed Pharmaceuticals Inc:Says Celgene Corp would develop and market six of its anti-cancer stem cell experimental drugs for an upfront payment of $155 million.Says it is eligible to receive up to $3 billion in option and payments if Celgene's option to license worldwide rights is exercised and approved.Says Celgene will also buy about $22.25 million of OncoMed's common stock for $15.13 per share. 

Company Quote

117.66
 --
26 Mar 2015